-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FOfKnAUpzobZFoc95S0x5i4chNlU3Zj38TC1oAJMM8rDB+Pb7BtJCaa+ZxNZ2ynr Hw7j7KOjMtJOaLPXhI4KJw== 0001104659-05-000565.txt : 20050106 0001104659-05-000565.hdr.sgml : 20050106 20050106142021 ACCESSION NUMBER: 0001104659-05-000565 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20041215 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20050106 DATE AS OF CHANGE: 20050106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEPHALON INC CENTRAL INDEX KEY: 0000873364 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232484489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19119 FILM NUMBER: 05515320 BUSINESS ADDRESS: STREET 1: 145 BRANDYWINE PKWY CITY: WEST CHESTER STATE: PA ZIP: 19380 BUSINESS PHONE: 6103440200 MAIL ADDRESS: STREET 1: 145 BRANDYWINE PARKWAY CITY: WEST CHESTER STATE: PA ZIP: 19380 8-K 1 a05-1145_18k.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported)    December 15, 2004

 

Cephalon, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

0-19119

23-2484489

(State or Other Jurisdiction

(Commission

(IRS Employer

of Incorporation)

File Number)

Identification No.)

 

 

 

145 Brandywine Parkway
West Chester, Pennsylvania

19380

(Address of Principal Executive Offices)

(Zip Code)

 

Registrant’s telephone number, including area code   (610) 344-0200

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 1.01               Entry into a Material Definitive Agreement.

 

On December 15, 2004, the Registrant and Abbott Laboratories entered into a First Amendment (the “First Amendment”) to Toll Manufacturing and Packaging Agreement dated October 31, 2000 (the “Agreement”). The effective date of the First Amendment is October 1, 2004.  The primary purpose of the First Amendment is:

 

•                  to extend the term of the Agreement until December 31, 2008 (subject to two consecutive two-year extensions unless prior written notice of non-renewal is provided by either party);

•                  to provide for appropriate notice to the Registrant if Abbott elects to no longer self-manufacture the active drug substance in GABITRIL; and

•                  to revise certain pricing terms for product delivered by Abbott.

 

2


 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

CEPHALON, INC.

 

 

 

 

Date: January 6, 2005

By:

 /s/ John E. Osborn

 

 

 

John E. Osborn

 

 

Sr. Vice President, General Counsel & Secretary

 

3

 -----END PRIVACY-ENHANCED MESSAGE-----